YTHDF1 and metabolic dysfunction-associated steatohepatitis: Functionally, Ythdf1 knockout or inhibition via LNP-siRNA significantly potentiates anti–PD-1 therapy, identifying YTHDF1 as a promising therapeutic target in NASH-HCC (18).